BACKGROUND (Details Narrative) - USD ($)			12 Months Ended
BACKGROUND (Details Narrative) - USD ($)	Jun. 10, 2020	Sep. 17, 2019	Dec. 31, 2021	Jun. 30, 2021	Jan. 31, 2021	Dec. 31, 2020	Oct. 31, 2020	Mar. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Debt securities sold								$ 250,000
Convertible preferred stock, par value			$ 0.0001			$ 0.0001
Reverse stock split	the Company’s Board of Directors approved a one-for-thirty (1-for-30) reverse stock split of the Company’s common stock	the Board of Directors approved a one-for-seventy-five (1-for-75) Reverse Stock Split.	1-for-75
Common stock shares issued			866,667
Payment for expenses and costs			$ 25,000
Proceeds from equity financing			$ 5,000,000
Percentage of issued and outstanding shares of common stock			54.14%
Inspyr Common Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			$ 0.0001
Inspyr Series A Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Rebus Series A Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Inspyr Series B Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Rebus Series B Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Inspyr Series C Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Rebus Series C Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Inspyr Series D Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Rebus Series D Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Inspyr Series E Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Rebus Series E Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Inspyr Series F Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Rebus Series F Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			$ 0.0001
Series F Preferred Stocks [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock			8,000
Cash [Member]
Finite-Lived Intangible Assets [Line Items]
Debt securities sold				$ 500,000	$ 500,000		$ 500,000
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Description of cancellation of a license agreement			In October 2020, pursuant to the cancellation of a license agreement whereby we previously licensed US Patent 9,593,118, we reacquired the exclusive right to such patent that covers both A2B and dual A2A/A2B antagonists. Accordingly, going forward our major focus will be to: (i) further characterization of the anti-cancer activity of our unique pipeline delivery platform containing A2B and dual A2A/A2B antagonists, leading to selection of a clinical candidate or candidates for an Investigative New Drug or IND enabling studies; and (ii) licensing and/or partnering our delivery platform and the A2B and dual A2A/A2B antagonists for further development.

Rebus Holdings, Inc. 10-K